• Vaccine Name: Cancer DNA Vaccine pLXSHDmB7-2 encoding Cd86
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011373
• Type: DNA vaccine
• Status: Research
• Antigen: Cd86
• Cd86 gene engineering:
  • Type: DNA vaccine construction
  • Description: A DNA fragment encoding the entire open reading frame of murine B7-2 was amplified by reverse transcription-coupled PCR (27) from RNA prepared from LPS-activated murine spleen cells (15). The sense primer (S’-TCGATAGGAATTCGTAGACGTGTTCCAGAACIT3’) consists of an oligonucleotide corresponding to 64 to 83 nucleotides of murine B7-2 cDNA, plus a restriction site for EcoRI. The antisense primer (5’-TACGATACTCGAGTCTCACTGCCTTCACTCTGCAT-3') corresponds to 1018 to 1039 nucleotides of murine B7-2 cDNA, plus a site for Xhol. The PCR product was cloned directly into the vector pLXSHD (provided by Dr. D. Miller, Fred Hutchinson Cancer Research Center, Seattle, WA) (Yang et al., 1995).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005012
• Immunization Route: Intraperitoneal injection (i.p.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: For immunization experiments, mice were injected into the shaved right back with live tumor cells by using the same procedure as described above, and tumor nodules were removed surgically at day 10 (Yang et al., 1995).
• Challenge Protocol: Two weeks after tumor removal, the mice were challenged into the left back or the frank with wt tumor cells at 1 X 10^5 /mouse (P815) or 2 X 10^5 /mouse (Yang et al., 1995).
• Efficacy: A plasmid containing murine B7-2 (Cd86) cDNA was transfected into the immunogenic mouse mastocytoma P815 of DBA/2 origin. In contrast to the lethal growth of the wild-type (wt) P815 tumor, B7-2-positive (B7-2+) P815 cells inoculated into syngeneic mice regressed, and immunization of mice with such tumor cells protected them against the challenge of wt P815 tumor (Yang et al., 1995).